🔗 Share this article

Given that America proceeds with unprecedented changes to its vaccination guidelines, one figure has emerged in a surprising turn: Høeg, a Danish American sports physician and public health researcher who initially gained attention by questioning Covid vaccinations during the global health crisis and has concentrated on alleged fatalities following COVID-19 immunization in her brief position at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Schedule

Agency leaders planned to reveal major revisions to the childhood immunization program earlier this month, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US out of step with much of the international standard with little proof for public health gain. The planned update has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is set to present at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to lead the division this year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending certain childhood immunization guidelines in the US to become more in line with Denmark, a society with nationalized medicine and a population roughly the population of Wisconsin’s.

So far statements, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Expertise

The appointee has little discernible experience in medication creation, oversight or management, which has been standard for former directors of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in managing a sizeable institution. She lacks background in industry regulation.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who ran CBER have had.”

This division has an immense range of responsibilities at the FDA, she emphasized.

“Many people just focuses on the novel medication approvals, but the generic program authorizes thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be looked after,” Dr. Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial leadership component to the role, which manages in excess of 5,000 employees. “It’s a enormous leadership role, if you perform it correctly,” Woodcock concluded.

Official Statement and Controversial Policies

In response to inquiries about Dr. Høeg's fitness for the role and whether this appointment indicates more teamwork among regulatory chiefs on vaccines, a spokesperson responded that the “concerns stem from inaccurate assumptions”.

“Her experience aligns with the responsibilities of her role,” the representative said, noting the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s new expedited review system, a contentious rapid therapy clearance system that allegedly worried her preceding directors. “How are these drugs being picked for this voucher program? Who is making the calls?” Howard questioned. “There’s a lot of confidentiality going on at the agency right now.”

Overall, he stated, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, with the exception of immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, history, some experts observe. She released a study using unconfirmed crowd-sourced reports to determine the rate of myocarditis following COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the current government included altering regulations for novel immunizations and discontinuing “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Høeg has reportedly floated the idea of preventing adolescent males from getting Covid vaccines.

“She’s an complete ideologue who commences with her preconceived notions and works backwards to fit the evidence in a very misleading, dishonest way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other dissenters, {like|